Ming-Yu Lai
Overview
Explore the profile of Ming-Yu Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun Y, Lu S, Lai M, Yang X, Guan W, Yang L, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):144.
PMID: 38832979
Background: The beneficial effects of first-line programmed death-1 (PD-1) inhibitors plus chemotherapy in patients with low programmed death-ligand 1 (PD-L1)-expressing advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma are controversial. Methods:...
2.
Li J, Lai M, Lin Z, Guan W, Sun Y, Yang J, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):132.
PMID: 38753055
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become the first-line treatment of metastatic gastric and gastroesophageal adenocarcinomas (GEACs). This study aims to figure out the optimal combined positive...
3.
Lai M, Guan W, Yang J, Sun Y, Lu S, Yang L, et al.
Clin Transl Oncol
. 2023 Aug;
26(3):765-773.
PMID: 37620706
Background: Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between...
4.
Qiu M, Chen Q, Zheng D, Zhao Q, Wu Q, Zhou Z, et al.
Cell Rep
. 2023 Jun;
42(6):112576.
PMID: 37285266
Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain...
5.
Liu Z, Zhang X, Zhao Q, Chen Y, Sheng H, He C, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2245836.
PMID: 36484990
Importance: The E-cadherin gene, CDH1, and the α-E-catenin gene, CTNNA1, were previously identified as hereditary diffuse gastric cancer (HDGC) susceptibility genes, explaining 25% to 50% of HDGC cases. The genetic...
6.
Lai M, Kang S, Sun Y, Quan T, Lu S, He C, et al.
BMC Cancer
. 2022 Oct;
22(1):1031.
PMID: 36183074
Background: Both Response Evaluation Criteria in Solid Tumors (RECIST) and tumor regression grade (TRG) play key roles in evaluating tumor response. We analyzed the consistency of TRG and RECIST 1.1...
7.
Li Z, Sun Y, Lai M, Zhou Y, Qiu M
Int Immunopharmacol
. 2022 May;
109:108790.
PMID: 35504202
Background: Different clinical trials for advanced esophageal cancer have investigated diverse immuno-oncology combinational treatment in first-line setting, but the optimal choice has not been identified. Methods: We used PubMed, Embase,...
8.
Hsu C, Huang B, Schnedler M, Lai M, Wang Y, Dunin-Borkowski R, et al.
Nat Commun
. 2021 Jun;
12(1):3893.
PMID: 34162864
High-temperature superconductive (SC) cuprates exhibit not only a SC phase, but also competing orders, suppressing superconductivity. Charge order (CO) has been recognized as an important competing order, but its microscopic...
9.
Jiang D, Tang G, Lai M, Huang Z, Liang Z
World J Clin Cases
. 2021 May;
9(14):3466-3471.
PMID: 34002159
Background: Cronkhite-Canada syndrome (CCS) is a rare nonhereditary disease characterized by chronic diarrhoea, diffuse gastrointestinal polyposis and ectodermal manifestations. The lethality of CCS can be up to 50% if it...
10.
Fu Z, Liu S, Qin M, Huang J, Xu C, Wu W, et al.
Oncol Rep
. 2018 Apr;
39(6):2721-2730.
PMID: 29620292
Systematic chemotherapy is indispensable for gastric cancer patients with advanced stage disease, but the occurrence of chemoresistance drastically limits treatment effectiveness. There is a tremendous need for identifying the underlying...